Related Experiment Videos
[Dyslipoproteinemia and chronic kidney failure]
J Zahálková1, H Vaverková, V Kristof
1III. interní klinika FN a LF UP, Olomouc.
Vnitrni Lekarstvi
|May 10, 2001
Summary
Chronic renal failure causes lipoprotein abnormalities, impacting triglyceride-rich lipoproteins and cholesterol transport. Treatments like fibrates, statins, and dietary changes can manage these lipid changes and reduce cardiovascular risk.
Area of Science:
- Nephrology
- Cardiology
- Metabolic Disorders
Context:
- Lipoprotein abnormalities are common in chronic kidney disease (CKD).
- Dyslipoproteinaemia severity correlates with renal function decline.
- Uremic environment negatively affects lipoprotein metabolism and reverse cholesterol transport.
Purpose:
- To explore the pathogenesis of lipid abnormalities in CKD.
- To understand the impact of uraemic dyslipoproteinaemia on renal disease progression and cardiovascular risk.
- To review therapeutic strategies for managing lipid disorders in CKD patients.
Summary:
- Uremic toxins impair triglyceride-rich lipoprotein metabolism and reverse cholesterol transport.
- Oxidation and glycation modify lipoproteins; nutritional factors also play a role.
- Dialysis modalities influence lipid profiles; fenofibrates and atorvastatin show potential benefits.
Impact:
- Renal dyslipoproteinaemia contributes to glomerular sclerosis and tubulointerstitial fibrosis.
- Accelerates atherosclerosis and increases cardiovascular mortality in CKD patients.
- Therapeutic interventions are crucial for mitigating renal and cardiovascular complications.